State of the Art Treatments for Cannabis Dependence

Psychiatric Clinics of North America

Volumn 35, Issue 2, 2012, Pages 309-326

  Danovitch, Itai ^a   Gorelick, David A ^b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Dependence; Endocannabinoids; Marijuana; Therapy; Treatment; Withdrawal

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ANANDAMIDE; ATOMOXETINE; BUSPIRONE; CANNABINOID 1 RECEPTOR AGONIST; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ENTACAPONE; FLUOXETINE; LITHIUM; LOFEXIDINE; NALTREXONE; NEFAZODONE; PLACEBO; RIMONABANT; VALPROATE SEMISODIUM;

ACADEMIC FAILURE; ALCOHOLISM; ANXIETY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CANNABIS ADDICTION; CANNABIS INTOXICATION; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); CRIMINAL BEHAVIOR; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DSM-III; DSM-IV; EDUCATIONAL STATUS; FAMILY THERAPY; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL DISEASE; HUMAN; ICD-10; INTOXICATION; MOOD DISORDER; MOTIVATIONAL ENHANCEMENT THERAPY; MOTIVATIONAL INTERVIEWING; OBESITY; OPEN STUDY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL IDEATION; SUPPORTIVE EXPRESSIVE PSYCHOTHERAPY; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANIMALS; CANNABINOIDS; COMBINED MODALITY THERAPY; COMORBIDITY; DEPRESSIVE DISORDER; ENDOCANNABINOIDS; HUMANS; MARIJUANA ABUSE; NEUROTRANSMITTER AGENTS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84861476270     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.03.003     Document Type: Review

References (126)

1. World drug report 2011. Sales No. E.11.XI.10 2011, United Nations Office on Drugs and Crime, United Nations Publication, Vienna (Austria).
2. Results from the 2010 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658 2011, Substance Abuse and Mental Health Services Administration, Substance Abuse and Mental Health Services Administration, Rockville (MD).
3. Degenhardt L., Chiu W.T., Sampson N., et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008, 5:e141.
4. Swift W., Hall W., Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Drug Alcohol Depend 2001, 63:147-153.
5. Johnston L.D., O'Malley P.M., Bachman J.G., et al. Monitoring the future national survey results on drug use, 1975-2010. Volume I: secondary school students 2011, Institute for Social Research, The University of Michigan, Ann Arbor.
6. Dennis M., Babor T.F., Rebuck M.C., et al. Changing the focus: the case for recognizing and treating cannabis use disorders. Addiction 2002, 97(Suppl 1):4-15.
7. McGlothlin W.H., West L.J. The marihuana problem: an overview. Am J Psychiatry 1968, 125:126-134.
8. Mechoulam R., Gaoni Y. A total synthesis of Dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965, 87:3273-3275.
9. Howlett A.C., Barth F., Bonner T.I., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
10. Cooper Z.D., Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 2008, 13:188-195.
11. Budney A.J., Hughes J.R., Moore B.A., et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004, 161:1967-1977.
12. Tanda G., Loddo P., Di Chiara G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 1999, 376:23-26.
13. Edwards G., Gross M.M. Alcohol dependence: provisional description of a clinical syndrome. Br Med J 1976, 1:1058-1061.
14. Diagnostic and statistical manual of mental disorders 1981, American Psychiatric Association, American Psychiatric Association, Washington, DC. 3rd edition (DSM-III).
15. Teesson M., Lynskey M., Manor B., et al. The structure of cannabis dependence in the community. Drug Alcohol Depend 2002, 68:255-262.
16. Stephens R.S., Babor T.F., Kadden R., et al. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction 2002, 97(Suppl 1):109-124.
17. Treatment episode data set (TEDS) highlights-2007: national admissions to substance abuse treatment services (DASIS Series: S-45, DHHS Publication No. SMA 09-4360) 2008, DHHS Office of Applied Studies, Author, Rockville (MD).
18. Fergusson D.M., Horwood L.J., Beautrais A.L. Cannabis and educational achievement. Addiction 2003, 98:1681-1692.
19. Crean R.D., Crane N.A., Mason B.J. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011, 5:1-8.
20. Solowij N., Stephens R.S., Roffman R.A., et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002, 287:1123-1131.
21. Solowij N., Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008, 1:81-98.
22. Dregan A., Gulliford M.C. Is illicit drug use harmful to cognitive functioning in the midadult years?. A cohort-based investigation. Am J Epidemiol 2012, 175:218-227.
23. Pope H.G., Gruber A.J., Hudson J.I., et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001, 58:909-915.
24. Medina K.L., Hanson K.L., Schweinsburg A.D., et al. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc 2007, 13:807-820.
25. Brook J.S., Lee J.Y., Brown E.N., et al. Developmental trajectories of marijuana use from adolescence to adulthood: personality and social role outcomes. Psychol Rep 2011, 108:339-357.
26. Fontes M.A., Bolla K.I., Cunha P.J., et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 2011, 198:442-447.
27. Fergusson D.M., Boden J.M. Cannabis use and later life outcomes. Addiction 2008, 103:969-976.
28. Macleod J., Oakes R., Copello A., et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004, 363:1579-1588.
29. Stinson F.S., Ruan W.J., Pickering R., et al. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006, 36:1447-1460.
30. Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry 2011, 68:138-147. Genetic Risk in Outcomes in Psychosis (GROUP) Investigators.
31. Bovasso G.B. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001, 158:2033-2037.
32. de Graaf R., Radovanovic M., van Laar M., et al. Early cannabis use and estimated risk of later onset of depression spells: epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol 2010, 172:149-159.
33. Kuepper R., van Os J., Lieb R., et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011, 342:d738.
34. Moore T.H., Zammit S., Lingford-Hughes A., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
35. Verweij K.J., Zietsch B.P., Lynskey M.T., et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 2010, 105:417-430.
36. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011, 68:148-157. Genetic Risk and Outcome of Psychosis (GROUP) Investigators.
37. Arseneault L., Cannon M., Witton J., et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004, 184:110-117.
38. Harder V.S., Morral A.R., Arkes J. Marijuana use and depression among adults: testing for causal associations. Addiction 2006, 101:1463-1472.
39. Aggarwal S.K., Carter G.T., Sullivan M.D., et al. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 2009, 5:153-168.
40. Arbour-Nicitopoulos K.P., Kwan M.Y., Lowe D., et al. Social norms of alcohol, smoking, and marijuana use within a Canadian university setting. J Am Coll Health 2011, 59:191-196.
41. Gates P., Copeland J., Swift W., et al. Barriers and facilitators to cannabis treatment. Drug Alcohol Rev 2011, [Epub ahead of print].
42. Hoffmann D.E., Weber E. Medical marijuana and the law. N Engl J Med 2010, 362:1453-1457.
43. Lewis T.F., Mobley A.K. Substance abuse and dependency risk: the role of peer perceptions, marijuana involvement, and attitudes toward substance use among college students. J Drug Educ 2010, 40:299-314.
44. Nutt D., King L.A., Saulsbury W., et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369:1047-1053.
45. Lozano B.E., Stephens R.S., Roffman R.A. Abstinence and moderate use goals in the treatment of marijuana dependence. Addiction 2006, 101:1589-1597.
46. Wilkins J.N., Gorelick D.A. Management of stimulant, hallucinogen, marijuana, phencyclidine, and club drug intoxication and withdrawal. Principles of addiction medicine 2009, 607-628. Lippincott Williams & Wilkins, Philadelphia. 4th edition. F.D. Ries, S.C. Miller, R. Saitz (Eds.).
47. Diagnostic and statistical manual of mental disorders (DSM-5), 2011 Accessed March 7, 2012. http://www.dsm5.org/.
48. Budney A.J., Hughes J.R. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006, 19:233-238.
49. Stephens R.S., Roffman R.A., Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000, 68:898-908.
50. Budney A.J., Moore B.A. Development and consequences of cannabis dependence. J Clin Pharmacol 2002, 42(Suppl 11):28S-33S.
51. Levin K.H., Copersino M.L., Heishman S.J., et al. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend 2010, 111:120-127.
52. Weinstein A.M., Gorelick D.A. Pharmacological treatment of cannabis dependence. Curr Pharm Des 2011, 17:1351-1358.
53. Vandrey R., Haney M. Pharmacotherapy for cannabis dependence: how close are we?. CNS Drugs 2009, 23:543-553.
54. Levin F.R., Kleber H.D. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict 2008, 17:161-164.
55. Haney M., Hart C.L., Vocburg S.K., et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004, 29:158-170.
56. Budney A.J., Vandrey R.G., Hughes J.R., et al. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007, 86:22-29.
57. Levin F.R., Mariani J.J., Brooks D.J., et al. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011, 116:142-150.
58. Bowen R., McIlwrick J., Baetz M., et al. Lithium and marijuana withdrawal. Can J Psychiatry 2005, 50:240-241.
59. Winstock A.R., Lea T., Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol 2009, 23:84-93.
60. Haney M., Ward S., Comer S.D., et al. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl) 2001, 155:171-179.
61. Haney M., Hart C.L., Ward A.S., et al. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 2003, 165:157-165.
62. Haney M., Hart C.L., Vosburg S.K., et al. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2008, 197:157-168.
63. Shafa R. COMT-inhibitors may be a promising tool in treatment of marijuana addiction. Am J Addict 2009, 18(AAAP 19th Annual Meeting Poster Abstracts):322.
64. Kau K.S., Madayag A., Mantsch J.R., et al. Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. Neuroscience 2008, 155:530-537.
65. Gray K.M., Watson N.L., Carpenter M.J., et al. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010, 19:187-189.
66. Tirado C.F., Goldman M., Lynch K., et al. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend 2008, 94:254-257.
67. McRae-Clark A.L., Carter R.E., Killeen T.K., et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 2010, 19:481-489.
68. McRae A.L., Brady K.T., Carter R.E. Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict 2006, 15:404.
69. McRae-Clark A.L., Carter R.E., Killeen T.K., et al. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009, 105:132-138.
70. Levin F.R., McDowell D., Evans S.M., et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004, 13:21-32.
71. Carpenter K.M., McDowell D., Brooks D.J., et al. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009, 18:53-64.
72. Cornelius J.R., Clark D.B., Bukstein O.G., et al. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav 2005, 30:1824-1833.
73. Cornelius J.R., Buksten O.G., Douaihy A.B., et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend 2010, 112:39-45.
74. Kano M., Ohno-Shosaku T., Hashimotodani Y., et al. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009, 89:309-380.
75. Parolaro D., Realini N., Vigano D., et al. The endocannabinoid system and psychiatric disorders. Exp Neurol 2010, 224:3-14.
76. Huestis M.A., Gorelick D.A., Heishman S.J., et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001, 58:322-328.
77. Huestis M.A., Boyd S.J., Heishman S.J., et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 2007, 194:505-515.
78. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009, 205:171-174.
79. Clapper J.R., Mangieri R.A., Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009, 56(Suppl 1):235-243.
80. Greenwald M.K., Stitzer M.L. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000, 59:261-275.
81. Wachtel S.R., de Wit H. Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend 2000, 59:251-260.
82. Haney M., Bisaga A., Foltin R.W. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 2003, 166:77-85.
83. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 2007, 32:1391-1403.
84. Cooper Z.D., Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl) 2010, 211:141-148.
85. Miller W., Rollnick S. Motivational interviewing: preparing people for change 2002, The Guilford Press, New York. 2nd edition.
86. Prochaska J.O., DiClemente C.C., Norcross J.C. In search of how people change. Applications to addictive behaviors. Am Psychol 1992, 47:1102-1114.
87. Babor T.F. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004, 72:455-466.
88. Stein L.A., Lebeau R., Colby S.M., et al. Motivational interviewing for incarcerated adolescents: effects of depressive symptoms on reducing alcohol and marijuana use after release. J Stud Alcohol Drugs 2011, 72:497-506.
89. Baker A., Turner A., Kay-Lambkin F.J., et al. The long and the short of treatments for alcohol or cannabis misuse among people with severe mental disorders. Addict Behav 2009, 34:852-858.
90. Kay-Lambkin F.J., Baker A.L., Lewin T.J., et al. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction 2009, 104:378-388.
91. Walker D.D., Roffman R.A., Picciano J.F., et al. The check-up: in-person, computerized, and telephone adaptations of motivational enhancement treatment to elicit voluntary participation by the contemplator. Subst Abuse Treat Prev Policy 2007, 2:2.
92. Baker A.L., Hides L., Lubman D.I. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry 2010, 71:247-254.
93. Martin G., Copeland J. The adolescent cannabis check-up: randomized trial of a brief intervention for young cannabis users. J Subst Abuse Treat 2008, 34:407-414.
94. Walker D.D., Roffman R.A., Stephens R.S., et al. Motivational enhancement therapy for adolescent marijuana users: a preliminary randomized controlled trial. J Consult Clin Psychol 2006, 74:628-632.
95. Stephens R.S., Roffman R.A., Fearer S.A., et al. The Marijuana Check-up: promoting change in ambivalent marijuana users. Addiction 2007, 102:947-957.
96. Beck A.T., Wright F.D., Newman C.F., et al. Cognitive therapy of substance abuse 2001, The Guilford Press, New York.
97. Copeland J., Swift W., Roffman R., et al. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat 2001, 21:55-64.
98. Stephens R.S., Roffman R.A., Simpson E.E. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol 1994, 62:92-99.
99. Stephens R.S., Roffman R.A., Copeland J., et al. Cognitive-behavioral and motivational enhancement treatments for cannabis dependence. Cannabis dependence: its nature, consequences and treatment 2006, 131-153. Cambridge University Press, Cambridge. R. Roffman, R. Stephens (Eds.).
100. Budney A.J., Higgins S.T., Radonovich K.J., et al. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000, 68:1051-1061.
101. Carroll K.M., Easton C.J., Nich C., et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J Consult Clin Psychol 2006, 74:955-966.
102. Baker A., Bucci S., Lewin T.J., et al. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2006, 188:439-448.
103. Budney A.J., Moore B.A., Sigmon S.C., et al. Contingency-management interventions for cannabis dependence. Cannabis dependence: its nature, consequences, and treatment 2006, 154-176. Cambridge University Press, Cambridge. R. Roffman, R. Stephens (Eds.).
104. Petry N.M. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug Alcohol Depend 2000, 58:9-25.
105. Budney A.J., Moore B.A., Rocha H.L., et al. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 2006, 74:307-316.
106. Kadden R.M., Litt M.D., Kabela-Cormier E., et al. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007, 32:1220-1236.
107. Sinha R., Easton C., Renee-Aubin L., et al. Engaging young probation-referred marijuana-abusing individuals in treatment: a pilot trial. Am J Addict 2003, 12:314-323.
108. Stanger C., Budney A.J., Kamon J.L., et al. A randomized trial of contingency management for adolescent marijuana abuse and dependence. Drug Alcohol Depend 2009, 105:240-247.
109. Sigmon S.C., Steingard S., Badger G.J., et al. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Exp Clin Psychopharmacol 2000, 8:509-517.
110. Misch D.A. Basic strategies of dynamic supportive therapy. J Psychother Pract Res 2000, 9:173-189.
111. Grenyer B.F.S., Luborsky L., Solowij N. Treatment manual for supportive-expressive dynamic psychotherapy: special adaptation for treatment of cannabis (marijuana) dependence 1995, National Drug and Alcohol Research Centre, Sydney (Australia).
112. Grenyer B., Solowij N., Peters R. A comparison of brief versus intensive treatment for cannabis dependence. Aust J Psychol 1996, 48(Suppl 106).
113. Diamond G., Leckrone J., Dennis M.L., et al. The Cannabis Youth Treatment Study: the treatment models and preliminary findings. Cannabis dependence; its nature, consequences and treatment 2006, 247-274. Cambridge University Press, Cambridge. R. Roffman, R.S. Stephens (Eds.).
114. Waldron H.B., Kern-Jones S., Turner C.W., et al. Engaging resistant adolescents in drug abuse treatment. J Subst Abuse Treat 2007, 32:133-142.
115. Rigter H., Pelc I., Tossmann P., et al. INCANT: a transnational randomized trial of multidimensional family therapy versus treatment as usual for adolescents with cannabis use disorder. BMC Psychiatry 2010, 10:28.
116. Liddle H.A., Dakof G.A., Turner R.M., et al. Treating adolescent drug abuse: a randomized trial comparing multidimensional family therapy and cognitive behavior therapy. Addiction 2008, 103:1660-1670.
117. Liddle H.A., Dakof G.A., Parker K., et al. Multidimensional family therapy for adolescent drug abuse: results of a randomized clinical trial. Am J Drug Alcohol Abuse 2001, 27:651-688.
118. Dennis M., Titus J.C., Diamond G., et al. The Cannabis Youth Treatment (CYT) experiment: rationale, study design and analysis plans. Addiction 2002, 97(Suppl 1):16-34.
119. Diamond G., Godley S.H., Liddle H.A., et al. Five outpatient treatment models for adolescent marijuana use: a description of the Cannabis Youth Treatment Interventions. Addiction 2002, 97(Suppl 1):70-83.
120. Brigham G.S. 12-step participation as a pathway to recovery: the Maryhaven experience and implications for treatment and research. Sci Pract Perspect 2003, 2:43-51.
121. Humphreys K. Professional interventions that facilitate 12-step self-help group involvement. Alcohol Res Health 1999, 23:93-98.
122. Marijuana 12 step workbook, 2008 Accessed October 21, 2011. http://www.marijuana-anonymous.org/ma12stepworkbook.shtml.
123. Stephens R., Roffman A. The nature, consequences and treatment of cannabis dependence: implications for future research and policy. Cannabis dependence: its nature, consequences and treatment 2006, 343-356. Cambridge University Press, Cambridge. A. Roffman, R. Stephens (Eds.).
124. Dutra L., Stathopoulous G., Basden S.L., et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008, 165:179-187.
125. McLellan A.T., Lewis D.C., O'Brien C.P., et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
126. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J Psychiatry Neurosci 2007, 32:30-52.